A new podcast episode explores the promise of this method to enable delivery of chemotherapies into the brain to combat a difficult-to-treat brain tumor.
Phase II Trial Evaluates Safety of Pembrolizumab plus SurVaxM in Recurrent Glioblastoma
Cleveland Clinic researchers are testing a novel immunotherapy/cancer vaccine combination in patients with recurrent glioblastoma, in hopes of finding an effective treatment for a condition with poor survival outcomes and a shortage of viable therapeutic options.